Synthetic biology investing in an age of open platforms - with Ursheet Parikh of Mayfield

John Cumbers
Published -
July 23, 2019

Today John Cumbers talks to Ursheet Parikh, partner at Mayfield and leader of their biotechnology and health care portfolios. The conversation is about what it takes to scale synthetic biology companies, some of the challenges they face, and how platform technologies in synthetic biology can help float all boats.


Ursheet is a proven repeat entrepreneur and executive who brings 15 years of product and leadership experience to the investment team at Mayfield. He focuses on innovation that is redefining the application and infrastructure stacks in cloud, mobile, enterprise technologies, genomics and digital health.


Ursheet’s current investments include Cloud Genix, Mission Bio, Mammoth Biosciences, Netsil, Qventus, Rancher Labs, Shiftleft, Versa Networks, and Zipongo.


Prior to joining Mayfield, he was an extremely successful leading manager at Microsoft and Cisco.


Thanks to Mayfield for making this episode possible.


Connect with Ursheet:

Connect with John:

Stay updated on the latest news in synthetic biology, check out our weekly newsletter and follow us on social media:

Twitter | LinkedIn | Facebook

Be sure you make it to SynBioBeta 2019 this October 1-3! Click here for more information.